Wird geladen...
Immune checkpoint inhibition in COVID-19: risks and benefits
INTRODUCTION: Immune checkpoint inhibition (ICI) is a novel cancer immunotherapy, which is administered in patients with metastatic, refractory, or relapsed solid cancer types. Since the initiation of the Coronavirus Disease 2019 (COVID-19) pandemic, many studies have reported a higher severity and...
Gespeichert in:
| Veröffentlicht in: | Expert Opin Biol Ther |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Taylor & Francis
2021
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7898453/ https://ncbi.nlm.nih.gov/pubmed/33543652 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14712598.2021.1887131 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|